IP Library Granted Patent US 11,234,992
Granted Patent B2
US 11,234,992 · App. 16/289,288 · Granted Feb 1, 2022

Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides

Inventors: Philip Gordts (San Diego, CA); Ariane Pessentheiner (San Diego, CA); Lars Bode (San Diego, CA)
Assignee: The Regents of the University of California
A61K31/7016A23L33/125A61K9/0095A61K9/14A61K9/20A61K9/4808A61K31/702A61K35/20A61P3/06A61P9/10A23V2002/00A23V2200/326A23V2200/3262A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,234,992
App. No.
16/289,288
Granted
Feb 1, 2022
Kind
B2
Abstract

The disclosure provides for therapies and methods to treat atherosclerosis and/or hyperlipidemia, and complications resulting therefrom, with compositions that comprise therapeutically effective amounts of one or more human milk oligosaccharides.

Claims (5)

1. A method of decreasing the size of aortic plaques or atherosclerotic lesions in a subject, in need thereof, the method comprising administering a composition comprising 3′ sialyllactose and 6′ sialyllactose at an amount effective to significantly reduce atherosclerotic lesions or aortic plaque size by suppressing inflammation caused by macrophages.

2. The method of claim 1 , further comprising administering the composition in combination with one or more drugs or therapeutic agents selected from cholesterol medications, anti-platelet medications, beta blocker medications, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, and diuretics.

3. The method of claim 1 , wherein the subject has one or more complications associated with atherosclerosis the one or more complications associated with atherosclerosis and/or hyperlipidemia are selected from coronary artery disease, heart failure, myocardial infarction, aneurysm, stroke, arrhythmia, peripheral arterial disease, chronic kidney disease, end-stage renal disease, renal artery stenosis, central retinal artery occlusion, central retinal vein occlusion, branch retinal artery occlusion, branch retinal vein occlusion, erectile dysfunction, and mesenteric ischemia.

4. The method of claim 1 , wherein the 3′-sialyllactose and 6′sialyllactose and pharmaceutically acceptable salts.

5. The method of claim 4 , wherein the pharmaceutically acceptable salts are sodium salts.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: GORDTS, PHILIP; BODE, LARS; PESSENTHEINER, ARIANE
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 058465/0018 →
Continuity (2)
Provisional Application 62636708 · Feb 28, 2018
Related Publication 20190269713A1 · Sep 5, 2019
Cited By (1)
US 12,383,569